Progenity (NASDAQ: PROG) is one of 42 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its rivals? We will compare Progenity to similar businesses based on the strength of its earnings, profitability, valuation, analyst recommendations, institutional ownership, risk and dividends.
Institutional & Insider Ownership
71.5% of Progenity shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Medical laboratories” companies are owned by institutional investors. 83.4% of Progenity shares are owned by company insiders. Comparatively, 17.8% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Progenity and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Progenity||$74.31 million||-$192.53 million||-0.36|
|Progenity Competitors||$931.62 million||$35.39 million||-40.96|
Progenity’s rivals have higher revenue and earnings than Progenity. Progenity is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares Progenity and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for Progenity and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Progenity presently has a consensus target price of $5.20, indicating a potential upside of 108.84%. As a group, “Medical laboratories” companies have a potential upside of 16.91%. Given Progenity’s higher possible upside, equities analysts clearly believe Progenity is more favorable than its rivals.
Progenity rivals beat Progenity on 7 of the 12 factors compared.
Progenity Company Profile
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
Receive News & Ratings for Progenity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenity and related companies with MarketBeat.com's FREE daily email newsletter.